SOHO State of the Art Updates and Next Questions | Sequencing Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
1/5 보강
Mantle cell lymphoma (MCL) is a rare non-Hodgkin lymphoma that, despite advances in treatment, remains incurable.
APA
Clement JM, Portell CA (2026). SOHO State of the Art Updates and Next Questions | Sequencing Therapies in Relapsed/Refractory Mantle Cell Lymphoma.. Clinical lymphoma, myeloma & leukemia, 26(4), e421-e429. https://doi.org/10.1016/j.clml.2026.01.008
MLA
Clement JM, et al.. "SOHO State of the Art Updates and Next Questions | Sequencing Therapies in Relapsed/Refractory Mantle Cell Lymphoma.." Clinical lymphoma, myeloma & leukemia, vol. 26, no. 4, 2026, pp. e421-e429.
PMID
41654478 ↗
Abstract 한글 요약
Mantle cell lymphoma (MCL) is a rare non-Hodgkin lymphoma that, despite advances in treatment, remains incurable. Clinical courses can range from indolent to aggressive. As understanding of the pathophysiology improves and more targeted therapies shift to the frontline setting, treatment of relapsed and refractory MCL is becoming less defined. This review discusses the evidence of current and emerging treatment strategies for patients with relapsed and refractory MCL, including Bruton tyrosine kinase inhibitor (BTKi) therapies and immunotherapies such as bispecific T-cell engagers and chimeric antigen receptor T-cells.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.